Designing a First-in-Human Dose-Escalation Study of a Selective Covalent FGFR2 Inhibitor in FGFR2-Altered Advanced Solid Tumors: Starting-Dose Rationale, BOIN Escalation, and Phase 1 Protocol Synopsis

A selective kinase inhibitor is designed to avoid the toxicities of its less selective predecessors, and its first-in-human study must show that selectivity translates into a tolerable dose that still engages the target. This article develops a hypothetical first-in-human study of an oral, highly selective, irreversible FGFR2 inhibitor in adults with advanced solid tumors carrying FGFR2 fusions or other activating alterations, with intrahepatic cholangiocarcinoma as the population of principal interest. It derives a 20 mg once-daily starting dose from assumed ICH S9 toxicology benchmarks, specifies five dose levels from 20 to 70 mg in continuous 28-day cycles, and uses a Bayesian optimal interval (BOIN) design with a 25% target dose-limiting toxicity rate, 18 to 30 participants, and Safety Review Committee review before every escalation. The synopsis focuses monitoring on toxicities linked to FGFR inhibition: hyperphosphatemia, ocular, skin, mucosal, hepatic, and gastrointestinal effects. The article explains why the healthy-volunteer starting-dose guidance is not applied mechanically and why FDA's dose-optimization guidance shapes the design.Keywords: first-in-human; FGFR2; covalent inhibitor; cholangiocarcinoma; BOIN design; ICH S9; dose optimization; Phase 1 protocol

Authors

Institutions

Publication Details

Journal
Zenodo (CERN European Organization for Nuclear Research)
Published
2026-11-21
DOI
https://doi.org/10.5281/zenodo.24426547
Primary Topic
Statistical Methods in Clinical Trials
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Designing a First-in-Human Dose-Escalation Study of a Selective Covalent FGFR2 Inhibitor in FGFR2-Altered Advanced Solid Tumors: Starting-Dose Rationale, BOIN Escalation, and Phase 1 Protocol Synopsis

Peivand Pirouzi, Riddhi Rohan Moradiya, Aditi Shivakumar Hipparagi
Zenodo (CERN European Organization for Nuclear Research)
Statistical Methods in Clinical Trials
article

Designing a First-in-Human Dose-Escalation Study of a Selective Covalent FGFR2 Inhibitor in FGFR2-Altered Advanced Solid Tumors: Starting-Dose Rationale, BOIN Escalation, and Phase 1 Protocol Synopsis

Peivand Pirouzi, Riddhi Rohan Moradiya, Aditi Shivakumar Hipparagi
article en

Abstract

A selective kinase inhibitor is designed to avoid the toxicities of its less selective predecessors, and its first-in-human study must show that selectivity translates into a tolerable dose that still engages the target. This article develops a hypothetical first-in-human study of an oral, highly selective, irreversible FGFR2 inhibitor in adults with advanced solid tumors carrying FGFR2 fusions or other activating alterations, with intrahepatic cholangiocarcinoma as the population of principal interest. It derives a 20 mg once-daily starting dose from assumed ICH S9 toxicology benchmarks, specifies five dose levels from 20 to 70 mg in continuous 28-day cycles, and uses a Bayesian optimal interval (BOIN) design with a 25% target dose-limiting toxicity rate, 18 to 30 participants, and Safety Review Committee review before every escalation. The synopsis focuses monitoring on toxicities linked to FGFR inhibition: hyperphosphatemia, ocular, skin, mucosal, hepatic, and gastrointestinal effects. The article explains why the healthy-volunteer starting-dose guidance is not applied mechanically and why FDA's dose-optimization guidance shapes the design.Keywords: first-in-human; FGFR2; covalent inhibitor; cholangiocarcinoma; BOIN design; ICH S9; dose optimization; Phase 1 protocol

Zenodo (CERN European Organization for Nuclear Research)
Northeastern University (US)
Statistical Methods in Clinical Trials
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon
Designing a First-in-Human Dose-Escalation Study of a Selective Covalent FGFR2 Inhibitor in FGFR2-Altered Advanced Solid Tumors: Starting-Dose Rationale, BOIN Escalation, and Phase 1 Protocol Synopsis — Peivand Pirouzi, Riddhi Rohan Moradiya, et al. · Zenodo (CERN European Organization for Nuclear Research) (2026) | TGRS Research Map | TGRS